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Abstract: High-mobility group box 1 (HMGB1) protein is a member of the highly conserved 
non-histone DNA binding protein family. First identified in 1973, as one of a group of chromatin-
associated proteins with high acidic and basic amino acid content, it was so named for its char-
acteristic rapid mobility in polyacrylamide gel electrophoresis. HMGB1 was later discovered 
to have another function. It is released from a variety of cells into the extracellular milieu to 
act on specific cell-surface receptors. In this latter role, HMGB1 is a proinflammatory cytokine 
that may contribute to many inflammatory diseases, including sepsis. Therefore, HMGB1 
regulates intracellular cascades influencing immune cell functions, including chemotaxis and 
immune modulation. The bioactivity of the HMGB1 is determined by specific posttranslational 
modifications that regulate its role in inflammation and immunity. During tumor development, 
HMGB1 has been reported to play paradoxical roles in promoting both cell survival and death 
by regulating multiple signaling pathways. In this review, we focus on the role of HMGB1 in 
physiological and pathological responses, as well as the mechanisms by which it contributes to 
immunity, inflammation, and cancer progression.
Keywords: alarmin, DNA replication, HMGB1, posttranslational modifications, wound 
repair
Introduction
The high-mobility group box 1 (HMGB1), a member of the high-mobility group (HMG) 
protein family, was identified in calf thymus in 1973 by Goodwin et al.1 The name 
“HMG” is derived from its high electrophoretic mobility in polyacrylamide gels.
HMG proteins are subdivided into three families named HMGB, HMGA, and 
HMGN. All HMGB proteins, including HMGB1–4, contain the functional HMG-box 
motif, have architectural functions, and are capable of organizing dynamic active 
chromatin structures. In adults, HMGB1 is expressed everywhere except in neurons, 
whereas HMGB2 and HMGB4 are expressed in the testes, and HMGB3 primarily in 
lymphoid organs.2 Prior to its naming, HMGB1 was also known as HMG1, ampho-
terin, and SBP-1.3
HMGB1 senses and coordinates the cellular stress response and plays a critical 
role not only inside of the cell as a DNA chaperone, chromosome guardian, autophagy 
sustainer, and protector from apoptotic cell death, but also outside the cell as the pro-
totypic damage-associated molecular pattern molecule (DAMP).4
Therefore, to elucidate the pleiotropic roles of HMGB1, in this review, we will 
emphasize the characteristics that make HMGB1 a critical molecular target in diseases 
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including infectious diseases, ischemia, immune disorders, 
neurodegenerative diseases, metabolic disorders, and 
cancer.
HMGB1: structural characteristics
HMGB1 is expressed in all vertebrate cells, in yeast, plants, 
and bacteria, localized in cytoplasm and nuclei. The protein 
abundance is high in thymus (106 molecules/cell) and in 
undifferentiated tissues; it is highly conserved through evolu-
tion, and has 99% identity among all mammals. It probably 
originated more than 500 million years ago, before the split 
between the animal and plant kingdoms.5
HMGB1 structure is composed of two tandem DNA-
binding HMG-box domains (N-terminal A and central B) 
and an acidic C-terminal tail, mediating protein–protein 
interactions (Figure 1).
HMGB1 is a 215 amino acid protein of 30 kDa, composed 
of three domains: two positively charged domains (A box and 
B box) and a negatively charged carboxyl terminus (acidic 
tail). This structure confers onto HMGB1 the peculiar feature 
to recognize and specifically bind DNA structures, containing 
sharp bends or kinks, such as four-way junctions.6,7
Structurally, HMGB1 consists of 215 residues orga-
nized in three main functional domains: the A and B boxes 
(positively charged) and the acidic tail (negatively charged). 
The A and B boxes, residues 1–79 and 89–163, respectively, 
are functionally DNA-binding domains.8,9
This region is composed of α-helical structures; in the 
nucleus, HMGB1 binds to the minor groove of linear DNA 
and bends it into a helical structure.10 The C-terminal acidic 
tail, residues 186–215, plays an important role in nuclear 
functions.11,12
At the N-terminus of HMGB1 (residues 6–12) is a hep-
arin-binding sequence that likely contributes to the heparin 
and heparin sulfate binding capacity of HMGB1.12
A C-terminal region of HMGB1 at amino acids 150–183 
mediates the receptor for advanced glycation end-product 
(RAGE) and Toll-like receptor (TLR) binding.13
The RAGE is a cell-bound receptor of the immunoglobu-
lin superfamily that is activated by a variety of proinflam-
matory ligands, including HMGB1, advanced glycation 
end-products, members of the S100 family of proteins, and 
amyloid β-peptide.14
Three cysteines (Cys) residues, crucial for the biological 
activities of extracellular HMGB1, are encoded within the 
HMGB1: two vicinal Cys in box A (C23 and C45) and a 
single one in box B (C106).15,16
Extracellular HMGB1 can bind and activate different sig-
naling transduction cell receptors, such as the receptor RAGE; 
the TLRs 2, 4, and 9; macrophage antigen-1; syndecan-3; 
CD24-Siglec-10; CXCR4; and certain integrin.17
RAGE is expressed in endothelial cells, vascular smooth 
muscle cells, monocytes, macrophages, dendritic cells, neu-
rons, and glial cells.18 The interaction of RAGE–HMGB1 
leads to the activation of different signal transduction path-
ways and culminates in cell responses ranging from cell 
motility to cell proliferation, as well as the production and 
release of cytokines/chemokines. RAGE blockade suppresses 
the HMGB1 effects, but only partially, strongly suggesting 
the existence of additional receptors for HMGB1. TLR2 and 
4 are involved in HMGB1-induced proinflammatory activa-
tion of macrophages and neutrophils. TLRs blockade does 
not completely abolish HMGB1 effect.
Recently, new receptor-mediating HMGB1 effects were 
demonstrated;19 these authors evaluated that at concentrations 
of agonist that were per se ineffective, HMGB1 potentiates 
the activation of the ionotropic glutamate N-methyl-d-
aspartate receptor, interacting with the ion channel through 
the sequence corresponding to the peptide located in the box 
B at the amino acids 130–139.9
Known roles in DNA replication, 
DNA repair, and transcription
HMGB1 is a member of the HMG family whose nuclear 
localization and affinity for DNA is regulated through 
phosphorylation and acetylation. HMGB1 has a dynamic 
N A box B box Acidic tail C
Cys23
1 79 89 163 186 215
Cys45 Cys106
Figure 1 Structure of HMGB1 protein.
Notes: HMGB1 is a 215-amino acid protein of 30 kDa. Structurally, HMGB1 is composed of three domains: two positively charged domains (A box and B box) and a 
negatively charged carboxyl terminus (acidic tail).
Abbreviations: Cys, cysteine; HMGB1, high-mobility group box 1.
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relationship with chromatin and plays an important role in 
DNA architecture and transcriptional regulation.20
HMGB1 is stored in the nucleus as a result of the pres-
ence of two lysine-rich nuclear localization sequences 
(NLSs) located in the box A (residues 28–44) and in the box 
B (residues 179–185). Hyperacetylation of NLSs promotes 
HMGB1 translocation from the nucleus to the cytosol, and 
the subsequent release of HMGB1.21
The subcellular localization of HMGB1 depends on the 
type and activation state of the cell. The HMGB1 is usu-
ally localized in the cell nucleus and diffusely distributed in 
cytoplasm.22 HMGB1 can be released from the nucleus to the 
extracellular space in response to different stimuli in two ways: 
following cellular injury it is passively released during cel-
lular apoptosis or necrosis; or it is released actively following 
inflammatory signals from activated immune cells or neuronal 
cells. Hyperacetylated HMGB1 molecules accumulate in the 
cytosol where they are packaged into secretory lysosomes and 
then released into the extracellular environment.23
HMGB1 binds the minor groove of DNA facilitating the 
assembly of site-specific DNA-binding proteins, including 
nuclear hormone/nuclear hormone receptor complexes and 
p53 or p73 transcriptional complexes.24
HMGB1 is involved in the facilitation of protein–protein 
interaction and recognition of DNA damage in the process 
of mismatch repair.25
HMGB1 is the structural protein of chromatin and regulates 
nuclear homeostasis and genome stability in several ways: 
HMGB1 binds to nucleosomes at the dyad axis, promotes 
nucleosome sliding, relaxes nucleosome structure, and makes 
chromatin more accessible by its ability to bend DNA.26
HMGB1 has been found to increase the binding affinity of 
many sequence-specific transcription factors to their cognate 
DNA, such as p53, p73, the retinoblastoma (Rb) protein, 
nuclear factor-κB (NF-κB), and the estrogen receptor.
HMGB1 directly binds to a variety of bulky DNA lesions 
which allows it to participate in DNA repair pathways includ-
ing nucleotide excision repair, base excision repair, mismatch 
repair, and double strand break repair via nonhomologous 
end-joining.
Loss of HMGB1 reduces telomerase activity, decreases 
telomere length, and increases chromosomal instability.27
HMGB1 as an alarmin: roles in 
inflammation, response to infection, 
and wound repair
For HMGB1 to function as a cytokine, it must be released 
into the extracellular milieu. HMGB1 is released passively 
during cellular necrosis by almost all cells that have a nucleus 
and signals neighboring cells of ongoing damage.
In 1999, Wang et al first reported that HMGB1 was liber-
ated from cells stimulated with cytokines and that HMGB1 
played an important role in mediating experimental sepsis.28 
Then, Scaffidi et al29 showed that HMGB1 is released from 
cells undergoing necrosis, but not from apoptotic cells, 
because HMGB1 is tightly bound to chromatin.
Recent reports demonstrate that HMGB1 can also be 
released by apoptotic cells,30 but in this case, the released 
HMGB1 appears to have a tolerogenic rather than a proin-
flammatory effect.31
Active secretion of HMGB1 is generally by nontradi-
tional, leaderless pathways which are not routed through the 
endoplasmic reticulum or Golgi apparatus. During normal 
cellular homeostasis the dynamic relationship of HMGB1 
with the nucleus and cytoplasm heavily favors the nucleus. 
However, HMGB1 concentrates in secretory lysosomes when 
hyperacetylated on lysine residues and then is released upon 
appropriate signaling stimuli.28
When HMGB1 is not acetylated, it remains localized to 
the nucleus and is not secreted or released, such as during 
apoptosis.31
Because HMGB1 does not contain a leader sequence, 
it is released via a nonclassical secretory pathway that 
may involve specialized vesicles of the endolysosomal 
compartment. Stimuli for secretion of HMGB1 are diverse 
and include pathogen-associated molecular patterns, cytok-
ines, and certain states of cellular stress.
HMGB1 can promote inflammatory responses by numer-
ous mechanisms. Comparisons of the necrotic cell debris 
from HMGB1-deficient and wild-type cells demonstrate that 
HMGB1-deficient cells have a profoundly reduced capacity 
to induce cytokines.29
Recombinant HMGB1 also induces cytokine produc-
tion from human monocytes but not from lymphocytes.32 
However, several groups have more recently shown that 
highly purified HMGB1 does not induce significant amounts 
of proinflammatory cytokines.6
However, it should also be noted that recombinant 
HMGB1 may be different from the native protein, with 
changes in the oxidative status having a profound impact on 
its biological activity.31
HMGB1 is not released only from cells of the immune sys-
tem; for other type of cells, it has been demonstrated an active 
secretion pathway. The first nonimmune cell to be studied for 
active HMGB1 secretion was the pituicyte, which was found 
to release HMGB1 in response to IL-1 or TNF stimulation.28
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Sepsis is a lethal syndrome after infection or injury, 
associated with a high mortality rate,33 and proinflammatory 
cytokines released from monocyte/macrophages and other 
cells have been implicated as important mediators of the 
lethal effect of endotoxin.28 Proinflammatory cytokines can 
lead to the development of tissue damage, metabolic acidosis, 
hypotension, multiple organ failure, and even death.33
Endogenous danger signals released from necrotic or 
stressed cells that trigger the inflammatory response after 
trauma have been termed alarmins or danger-associated 
molecular patterns (DAMPs).
HMGB1 was recognized as a late mediator of sepsis in 
animal models of systemic endotoxemia.28 Therapy with 
anti-HMGB1 antibodies before or after endotoxin exposure 
confers significant protection against lethality, and adminis-
tration of HMGB1 itself was lethal, suggesting that HMGB1 
is an endogenous mediator of endotoxin lethality.28
Some research reported that cytokines may stimulate 
release of HMGB1 from pituicytes and astrocytes.34 These 
findings suggest a role for HMGB1 in neurological disorders. 
It also demonstrates that HMGB1 is highly expressed in 
mouse brain neurons and astrocytes, is released during 
brain ischemia, and contributes to neuroinflammation and 
postischemic brain damage.35
Clinical studies have demonstrated that HMGB1 is a late 
mediator of sepsis and some investigations have reported 
elevated serum/plasma HMGB1 concentrations in patients 
with sepsis.28
Until now, it was not known to what extent local HMGB1 
release contributes to serum HMGB1 levels, and to what 
extent it contributes to damage at the site of infection and to 
distant organs in patients with sepsis.33 It has been reported 
that genetic variation in the HMGB1 gene could affect the 
outcome of patients with systemic inflammatory response 
syndrome and sepsis, suggesting a possible role for HMGB1 
genetics.36
More recently, HMGB1 has been associated, as a putative 
danger signal, to pathogenesis of a variety of noninfectious 
inflammatory conditions, ie, autoimmunity, trauma, hemor-
rhagic shock, and ischemia-reperfusion injury.37 Furthermore, 
a role for HMGB1 has been suggested in some normal and 
pathological conditions for a huge number of organs and sys-
tems including liver, heart, pancreas, brain, bone, and kidney.38 
In fact, HMGB1 levels are elevated in patients with mechani-
cal trauma, such as strokes, acute myocardial infarction, acute 
respiratory distress, and liver transplantation.39,40 This pleiotro-
pic inflammatory role for HMGB1 could be due to the exis-
tence of multiple receptors that mediate HMGB1 responses. 
The different responses to HMGB1 stimulation may rely on 
the levels of HMGB1, on the expression of the receptors in the 
target organ, and on the ability of HMGB1 to interact with 
other molecules. Potentially, there is significant cross talk 
between receptors, and the deficient or defective receptor may 
influence the function of other receptors.41
There is growing interest in the role of alarmins, such as 
HMGB1, in contrast to their role in promoting inflammation, 
to promote tissue repair and regeneration.42 HMGB1 may act 
as a trigger of tissue repair, recruiting stem cells and promot-
ing their proliferation.43
The physiological meaning of the role of HMGB1 in 
wound healing remains to be elucidated. For cutaneous 
wound healing, some studies42,44 allowed us to postulate that 
HMGB1 release may occur from skin cells as the result of cell 
activation, enhanced membrane permeability, or membrane 
ruptures. After its release in the wounded area, HMGB1 could 
operate the recruitment of different cell types, influencing 
keratinocyte and fibroblast proliferation and migration.42
Taken together, the regenerative properties of HMGB1 
represent a potentially important way by which the functions 
of such alarmin can be manipulated to promote healing as 
opposed to injury.
Emerging roles in innate  
and adaptive immunity  
and autoimmunity
It has also been found that HMGB1 behaves as an endoge-
nous immune adjuvant.45 HMGB1 elicits a striking increase in 
the titers of high-affinity hypermutated IgG when coinjected 
with the soluble nominal antigen ovalbumin. Moreover, it 
was sufficient to reconstitute the immunogenicity of apoptotic 
“self ” cells in vivo.46
HMGB1 triggers inflammation, attracting other cells, 
inducing tissue repair, recruiting stem cells, and promoting 
their proliferation. HMGB1 also activates dendritic cells 
and promotes their functional maturation and their response 
to lymph node chemokines. Therefore, HMGB1 acts in an 
autocrine/paracrine fashion and sustains long-term repair 
and defense programs. HMGB1 secretion is critical for the 
immunity system because dendritic cells, when reaching the 
lymph nodes, secrete HMGB1, sustaining the proliferation of 
antigen-specific T-cells, to prevent their activation-dependent 
apoptosis, and to promote their polarization toward a T-helper 
1 phenotype.46
Considerable evidence suggests the implication of 
extracellular HMGB1 in the pathogenesis of a variety of 
autoimmune diseases.
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Anti-HMGB1 antibodies are present in the serum of 
patients with rheumatoid arthritis and drug-induced systemic 
lupus erythematosus.47 HMGB1 is overexpressed in synovial 
biopsy specimens of rheumatoid patients and in experimental 
arthritis.48
HMGB1 induces arthritis in mice, while treatment with 
HMGB1 antagonists ameliorates collagen-induced arthritis 
in both rats and mice.49
Increased extracellular HMGB1 is also detectable in 
the dermis and epidermis of skin lesions in patients with 
cutaneous lupus erythematosus and in biopsy specimens 
of the minor salivary glands of patients with Sjogren’s 
syndrome.50
In multiple sclerosis, HMGB1 expression was found to be 
upregulated in brain active lesions from patients.51 In the ani-
mal model of multiple sclerosis, experimental autoimmune 
encephalomyelitis, neutralization of HMGB1 ameliorated 
clinical severity, reduced central nervous system pathology, 
and blocked proinflammatory cytokine production.52
New recent data support a novel concept of brain– immune 
interaction after acute brain lesions in which soluble danger 
signals from the brain mediate a complex immune-mod-
ulatory reaction in the peripheral immune system.53,54 The 
HMGB1-RAGE-mediated pathway could be a key mecha-
nism explaining the complex postischemic brain–immune 
interactions. This mechanism indicates that the cytokine-
 inducing, fully reduced isoform of HMGB1 was released 
from the ischemic brain in the hyperacute phase of stroke 
in mice and patients. Cytokines secreted in the periphery in 
response to brain injury induced sickness behavior, which 
could be abrogated by inhibition of the HMGB1-RAGE path-
way or direct cytokine neutralization.54 Therefore, HMGB1 in 
the central nervous system could a useful biomarker and may 
contribute to the chronicity of neuroinflammation through 
the proposed positive-feedback loop involving infiltrating 
macrophages and resident microglia.51
Posttranslational modifications  
and molecular interactions  
in HMGB1 function
HMGB1 contains three Cys residues, which are critical for 
the biological activity of the protein (Figure 2). Cys are modi-
fied by different redox signals with oxidation of thiol group 
side-chains (-SH) to several reversible redox states, such as 
disulfide (R-S-S-R), sulfenic acid (R-SOH), and sulfonate 
(R-SO
3
H) moieties.37
HMGB1 can form a Cys23–Cys45 intermolecular disul-
fide bond, while the Cys106 remains in the reduced form.15
Replacement of Cys23 and/or Cys45 with serines did 
not affect the nuclear distribution of the mutant proteins, 
whereas C106 and triple Cys mutations impaired nuclear 
localization of HMGB1.55
The redox status of HMGB1 recognized its cytokine-
inducing and chemokine activity.16 C106 is necessary for the 
binding of HMGB1 to TLR4 to stimulate cytokine release 
and inflammation.56
Recent observations suggested that the disulfide bond 
between C23 and C45 is also required for HMGB1 cytokine 
activity.16 Indeed, mutations of C45 or C23 abolish HMGB1 
cytokine-inducing activity.
N
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Acidic
tail
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SO3H
Oxidized cysteine
Disulfide HMGB1
Reduced cysteine
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C
Figure 2 Redox modulation of HMGB1 activity.
Notes: Different HMGB1 redox states: (A) all-oxidized cysteine in HMGB1, by reactive oxygen species, abrogates cytokine-inducing activity; (B) a disulfide bond induces 
cytokine cell release; (C) a reduced cysteine form has chemoattractant activity.
Abbreviation: HMGB1, high-mobility group box 1.
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Reactive oxygen species oxidizes HMGB1 at C106 
released from apoptotic cells, thereby neutralizing its 
cytokine potential.31 All-cysteine-oxidized HMGB1 confor-
mation prevents HMGB1’s cytokine or chemokine activity.16 
Therefore, the redox modifications of HMGB1 play a cru-
cial role for the protein functionality during infection and 
inflammation.56
The complex and fine-tuned process of autophagy is also 
regulated by HMGB1 activities. During stress, starvation, 
oxidative stress, and chemotherapy, HMGB1 translocate from 
nucleus to cytoplasm for binding beclin-1, which initiates the 
autophagosome process. The intramolecular disulfide bond 
(C23–C45) of HMGB1 is required for binding beclin-1. 
Once released, this reduced-HMGB1 triggers autophagy in 
a RAGE-dependent manner in cancer cells.56
The functional in vivo relevance of redox-modified 
HMGB1 has been confirmed in experimental animal 
models.20
HMGB1 may undergo other extensive posttranslational 
modifications, including reversible acetylation, methylation, 
ADP ribosylation, glycation, and phosphorylation.57
Acetylation of key lysine residues within the two NLS 
sites of HMGB1 is a regulatory mechanism for intracellular 
shuttling, allowing the release of protein from activated 
monocytes and macrophages.58 Hyperacetylation of these 
residues unbalances the HMGB1 from its nuclear position 
toward  cytoplasmic accumulation and its continuous shuttling 
between nucleus and cytoplasm.59 The acetylated HMGB1 in 
serum of patients is a specific biomarker of acetaminophen-
induced hepatotoxicity that is useful for clinical outcome.60 
Other findings suggest that the hyperacetylated HMGB1 is 
a newly identified biomarker for pyroptosis. Pyroptosis is a 
proinflammatory cell-death mode associated with osmotic 
lysis and the release of the intracellular content into the extra-
cellular milieu.61 Redox status of three Cys of HMGB1 suggest 
that HMGB1 released during pyroptosis may contain active 
(disulfide-bonded) form, whereas HMGB1 during necrosis 
may contain all-thiol forms. Moreover, other observations 
revealed that HMGB1 released during pyroptosis is acetylated. 
So, HMGB1 released during pyroptosis can subsequently be 
detected by TLR4 and RAGE receptors to stimulate cytokine 
release and cell migration.61,62
Emerging roles in the pathogenesis 
of cancer: HMGB1 as a therapeutic 
target?
There is growing evidence that HMGB1 may be associated 
with hallmarks of cancer such as: unlimited replicative 
potential ability to develop blood vessels (angiogenesis); 
 evasion of programmed cell death (apoptosis); self- sufficiency 
in growth signals; insensitivity to inhibitors of growth; 
inflammation; tissue invasion and metastasis; and enhance-
ment of inflammation.63
HMGB1 is one of the most cancer-specific genes. Over-
expression of HMGB1 in tumor tissue and increased HMGB1 
serum level are near-universal in solid tumors, including colon, 
gastric, lung, breast, ovarian, pancreatic, and prostate cancer.27
Serum HMGB1 levels were significantly associated with 
depth of invasion, lymph node metastasis, tumor size, and 
poor prognosis. The selective upregulation of HMGB1 in 
tumors contrasts with the other DAMPs, which are expressed 
under normal conditions and display only modest increased 
expression in malignancy.64
Interestingly, the mechanisms by which HMGB1 expres-
sion is normally suppressed are not fully elucidated. We know 
that HMGB1 can associate with other molecules, including 
DNA and cytokines, and activate cells through the differential 
surface receptors such as TLR4, RAGE, CD24, and TIM-3, 
influencing the cancer cell’s fate through the cross talk of 
many different pathways.65
HMGB1 functions as a tumor suppressor in breast cancer, 
binding to well-known tumor suppressor protein Rb,66 caus-
ing Rb-dependent G1 arrest and apoptosis induction. The 
overexpression of HMGB1 inhibits Rb-positive breast cancer 
cells growth in vitro, also preventing growth in in vivo tumor 
models.67
Genomic instability is a hallmark of most cancers.68 Some 
studies also demonstrate that mammalian HMGB1 and its yeast 
homologue are critical for maintaining genome  stability.68,69 
High levels of aneuploidy and spontaneous chromosome aber-
rations were observed in HMGB1-deficient mouse embryonic 
fibroblasts (MEFs).69
HMGB1 is involved in major DNA repair pathways, but 
it could interact with telomerase catalytic component as well 
as DNA repair enzymes and cofactors to regulate telomere 
length and DNA repair efficiency.70 The complex roles of 
HMGB1 in coordinating DNA repair and genomic stability 
should be further elucidated.
The tumor growth is normally accompanied by reduced 
microvessel density, therefore resulting in chronic hypoxia. 
These hypoxic and necrotic regions exhibit increased expres-
sion of angiogenic growth factors, recruiting macrophages 
which produce some angiogenetic cytokines and growth 
factors.71
Activation of HMGB1 and its receptor RAGE results in 
the activation of NF-κB pathway, which in turn upregulates 
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leukocyte adhesion molecules and the production of proin-
flammatory cytokines and angiogenic factors, thereby pro-
moting inflammation and angiogenesis.72 Antibody-targeting 
HMGB1 inhibits angiogenesis in vitro and in vivo.72
Several HMGB1-targeting agents have been already used 
in cancer research. These agents include soluble RAGE, 
HMGB1-neutralizing antibody, platinating agent, ethyl 
pyruvate, quercetin, and glycyrrhizin.27 HMGB1-neutralizing 
antibody can block activity of extracellular HMGB1 in tumor 
therapy.73 Blockade of RAGE signaling pathways could also 
result in attenuation of tumor development and growth.  Several 
strategies that block HMGB1-RAGE signaling have been 
described.74 Soluble RAGE acts as a decoy to prevent RAGE 
signaling and has been used successfully in animal models.75 
Platinating agents such as cisplatin and oxaliplatin have the 
ability to retain HMGB1 within the nucleus.76 HMG domain 
motifs bind specifically to the major platinum DNA adducts, 
creating a shield against the human excision nucleases accom-
plished through the HMGB1 acidic domain.77 Ethyl pyruvate, 
the first HMGB1 inhibitor used in animal models, inhibits 
the release of TNF and HMGB1 from endotoxin-stimulated 
murine macrophages, and also attenuates activation of both 
the p38 mitogen-activated protein kinase and NF-κB signaling 
pathways.78 Ethyl pyruvate, interacting with NF-κB, inhibits 
liver tumor growth.79 In addition, glycyrrhizin and quercetin, 
potential HMGB1 inhibitors by direct binding to HMGB1 or 
inhibition of PI3K, improve the effectiveness of anticancer 
agents in several different tumor models.63 So, targeting the 
HMGB1 or its receptor represents an important potential 
application in cancer therapy.80
Conclusion
In 1973, the discovery of HMGB1 as a non-histone chromo-
somal protein was reported. HMGB1 in the nucleus regulates 
a number of DNA-related mechanisms.1 In 1999, with the 
discovery of HMGB1 as a late mediator of sepsis, a new 
research field was born.28 During the past years, HMGB1 
receptors, which balance its activity in multiple cellular 
processes, have been isolated. In addition to its receptors, 
HMGB1 posttranslational modifications play an important 
role in mediating HMGB1 activity.23
Intracellular and extracellular HMGB1 play significantly 
different roles in inflammation, injury, and cancer. A new 
function for HMGB1 is as an autophagy regulator, linking 
the HMGB1 to sterile inflammation, infection, neurodegen-
erative disease, and cancer.4
Few molecules have as many structures and functions 
as HMGB1. The understanding of molecular plasticity and 
multiplicity of HMGB1 is an exciting focus of research, in par-
ticular as a prototype for development of anti-inflammatory and 
immunosuppressive therapies. Future work investigating the 
details of HMGB1 location, structure, modification, and partners 
will uncover the secrets of HMGB1’s multiple functions.
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